PVLA
Palvella Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +27.3% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 494.66K | +202.0% | $31.01M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 487.62K | +9.6% | $30.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 3 | Point72 Asset Management ✦ | 317.31K | New | $19.89M | 0.0% | New | 1 | SEC ↗ |
| 4 | Goldman Sachs Group ✦ | 236.63K | n/a | $14.83M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 168.11K | -3.4% | $10.54M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 6 | Morgan Stanley ✦ | 138.50K | n/a | $8.68M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 7 | State Street Global Advisors ✦ (passive) | 137.25K | +67.4% | $8.60M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Fidelity (FMR) ✦ | 110.45K | +108180.4% | $6.92M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 89.70K | +34.2% | $5.62M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Millennium Management ✦ | 26.87K | -91.5% | $1.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Wellington Management ✦ | 23.70K | New | $1.49M | 0.0% | New | 1 | SEC ↗ ×3 |
| 12 | JPMorgan Chase ✦ | 8.68K | n/a | $543,898 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 13 | Two Sigma Investments ✦ | 4.09K | New | $256,402 | 0.0% | New | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 3.66K | New | $230,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $19.89M | 0.0% |
| Wellington Management | $1.49M | 0.0% |
| Two Sigma Investments | $256,402 | 0.0% |
| T. Rowe Price | $230,000 | 0.0% |
Exited
| Marshall Wace | $1.11M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 181 holders, 13.20M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 476 sh · $57,663
Director · 505 sh · $63,910
Director · 597 sh · $74,820
Director · 920 sh · $114,416
Director · 2.60K sh · $321,046
Director · 2.07K sh · $254,058
Director · 1.64K sh · $212,455
Director · 922 sh · $123,292
Director · 579 sh · $76,662
Director · 1.03K sh · $136,092
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology